REPL Replimune Group, Inc. Stock Quote

REPL [NASD]

Index	-	P/E	-	EPS (ttm)	-1.77	Insider Own	14.50%	Shs Outstand	44.02M	Perf Week	-2.72%
Market Cap	2.04B	Forward P/E	-	EPS next Y	-1.87	Insider Trans	-12.27%	Shs Float	41.72M	Perf Month	10.41%
Income	-69.60M	PEG	-	EPS next Q	-0.42	Inst Own	78.10%	Short Float	6.45%	Perf Quarter	7.05%
Sales	-	P/S	-	EPS this Y	-15.60%	Inst Trans	1.07%	Short Ratio	5.05	Perf Half Y	124.00%
Book/sh	5.94	P/B	7.46	EPS next Y	-6.90%	ROA	-24.70%	Target Price	55.70	Perf Year	146.69%
Cash/sh	5.31	P/C	8.35	EPS next 5Y	-	ROE	-30.20%	52W Range	8.58 - 54.85	Perf YTD	16.20%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-19.18%	Beta	-
Dividend %	-	Quick Ratio	19.50	Sales past 5Y	-	Gross Margin	-	52W Low	416.67%	ATR	2.51
Employees	122	Current Ratio	19.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	55.36	Volatility	6.15% 6.44%
Optionable	Yes	Debt/Eq	0.14	EPS Q/Q	-29.80%	Profit Margin	-	Rel Volume	0.60	Prev Close	44.44
Shortable	Yes	LT Debt/Eq	0.13	Earnings	-	Payout	-	Avg Volume	532.50K	Price	44.33
Recom	1.60	SMA20	6.39%	SMA50	0.05%	SMA200	54.27%	Volume	321,840	Change	-0.25%

Nov-17-20

Initiated

BTIG Research

Buy

$60

Nov-02-20

Initiated

Jefferies

Buy

$67

Oct-15-20

Upgrade

H.C. Wainwright

Neutral → Buy

$25 → $54

Jul-01-20

Downgrade

H.C. Wainwright

Buy → Neutral

$25

May-05-20

Initiated

Barclays

Overweight

$21

Sep-04-19

Initiated

ROTH Capital

Buy

$20

Jul-23-19

Initiated

Chardan Capital Markets

Buy

$28

Jul-12-19

Upgrade

JP Morgan

Neutral → Overweight

$27 → $26

Jul-08-19

Initiated

H.C. Wainwright

Buy

$26

Apr-25-19

Initiated

Wedbush

Outperform

$24

Jan-23-19

Downgrade

JP Morgan

Overweight → Neutral

Aug-14-18

Initiated

Leerink Partners

Outperform

$25

Aug-14-18

Initiated

JP Morgan

Overweight

$26

Jan-11-21 07:00AM	Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones GlobeNewswire
Jan-06-21 08:00AM	Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.40%
Jan-05-21 08:00AM	Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors GlobeNewswire
Dec-12-20 09:48PM	Is REPL A Good Stock To Buy Now? Insider Monkey
Nov-12-20 08:00AM	Replimune to Participate at the SVB Leerink Oncology 1x1 Day GlobeNewswire -5.40%
Nov-09-20 08:00AM	Replimune Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference GlobeNewswire -5.16%
Nov-05-20 08:00AM	Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update GlobeNewswire
Oct-27-20 09:42AM	Is Replimune Group, Inc. (NASDAQ:REPL) Popular Amongst Insiders? Simply Wall St. +5.18%
Oct-22-20 01:09AM	Replimune Announces Pricing of Upsized Public Offering GlobeNewswire
Oct-20-20 04:02PM	Replimune Announces Proposed Public Offering GlobeNewswire
04:01PM	Replimune Releases Updated Corporate Presentation GlobeNewswire
Oct-19-20 04:01PM	Replimune Appoints Tanya Lewis to the Board of Directors GlobeNewswire
Oct-15-20 11:33AM	Why Replimune Stock Is Soaring Today Motley Fool +13.02%
09:51AM	Benzinga's Top Upgrades, Downgrades For October 15, 2020 Benzinga
Oct-14-20 12:29PM	Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire +46.82%
Aug-07-20 07:00AM	Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update GlobeNewswire +11.09%
Aug-04-20 07:00AM	Replimune to Present at Two Upcoming Investor Conferences GlobeNewswire
Jul-22-20 07:00AM	Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer GlobeNewswire -5.16%
Jun-22-20 02:27PM	Replimune Group, Inc. (REPL): Hedge Funds Are Reducing Exposure Insider Monkey
Jun-17-20 08:00AM	Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-11-20 08:47AM	Replimune (REPL) Looks Good: Stock Adds 5.8% in Session Zacks
Jun-08-20 11:21PM	Replimune Announces Pricing of Upsized Public Offering GlobeNewswire
04:16PM	Replimune Announces Proposed Public Offering GlobeNewswire
Jun-03-20 07:15AM	Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire
07:00AM	Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimunes Ongoing Registration-Directed Clinical Trials with RP1 GlobeNewswire
Apr-30-20 06:00AM	Replimune to Provide Data Update on June 3, 2020 GlobeNewswire +20.84%
Apr-02-20 07:00AM	Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors GlobeNewswire
Feb-13-20 07:00AM	Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update GlobeNewswire
Feb-06-20 08:00AM	Replimune to Present at Two Upcoming Investor Conferences GlobeNewswire -5.08%
Jan-13-20 07:00AM	Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones GlobeNewswire
Jan-09-20 07:00AM	Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization GlobeNewswire
Jan-07-20 08:00AM	Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference GlobeNewswire
Dec-23-19 02:56PM	Replimune Group, Inc. (NASDAQ:REPL): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-09-19 08:00AM	Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer GlobeNewswire
Nov-26-19 08:00AM	Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-22-19 12:13PM	Largest Insider Trades of the Week GuruFocus.com
Nov-14-19 06:22AM	Replimune Announces Pricing of Public Offering GlobeNewswire
Nov-12-19 04:06PM	Replimune Announces Proposed Public Offering GlobeNewswire
Nov-11-19 08:00AM	Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-19 07:30AM	Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC) GlobeNewswire
Oct-31-19 04:00PM	Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) GlobeNewswire
02:19PM	Is Replimune Group, Inc. (REPL) A Good Stock To Buy? Insider Monkey
Oct-24-19 08:00AM	Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer Patients GlobeNewswire
Oct-15-19 07:00AM	Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma GlobeNewswire +15.02%
Oct-02-19 08:00AM	Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire -5.77%
Oct-01-19 08:00AM	Replimune to Present at Chardans 3rd Annual Genetic Medicines Conference GlobeNewswire -5.25%
Sep-13-19 04:39AM	2 Downtrodden Small Biotechs That Are Showing Signs of Life TheStreet.com
Aug-14-19 08:00AM	Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update GlobeNewswire
Aug-06-19 08:00AM	Replimune to Present at 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire -5.53%
Jul-19-19 09:16AM	Imagine Owning Replimune Group (NASDAQ:REPL) And Wondering If The 17% Share Price Slide Is Justified Simply Wall St.
Jun-28-19 08:00AM	Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update GlobeNewswire +6.15%
Jun-01-19 09:00AM	Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab GlobeNewswire
May-30-19 08:00AM	Replimune to Present at Upcoming Investor Conferences GlobeNewswire
May-16-19 07:00AM	Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire +5.80%
Apr-25-19 02:23PM	Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation Benzinga +6.65%
Apr-01-19 07:00AM	Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Feb-14-19 08:00AM	Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update GlobeNewswire
Feb-07-19 08:00AM	Replimune to Present at Two Upcoming Investor Conferences GlobeNewswire
Jan-04-19 12:33PM	How Much Are Replimune Group, Inc. (NASDAQ:REPL) Insiders Spending On Buying Shares? Simply Wall St.
Jan-03-19 08:00AM	Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference GlobeNewswire
Dec-20-18 08:00AM	Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference GlobeNewswire
Dec-08-18 06:19PM	RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy? Insider Monkey
Dec-05-18 08:00AM	Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-14-18 08:38AM	Bain Capital Life Sciences Investors, LLC Buys Replimune Group Inc GuruFocus.com
08:00AM	Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update GlobeNewswire
Sep-26-18 08:00AM	Replimune to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Sep-06-18 04:01PM	Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1 GlobeNewswire
Aug-30-18 08:00AM	Replimune Reports Financial Results for the First Fiscal Quarter, Ended June 30, and Provides Development and Corporate Update GlobeNewswire -9.20%
Aug-14-18 02:49PM	BMO Sees A Low-Risk Biotech Buy In Replimune Benzinga
Jul-24-18 07:44AM	[$$] Gormley's Take: Public Markets' Embrace of Health Care Extends Beyond Biotech The Wall Street Journal

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Esposito Pamela	Chief Business Officer	Jan 19	Option Exercise	1.01	5,727	5,784	181,721	Jan 19 09:50 PM
Astley-Sparke Philip	Chief Executive Officer	Jan 19	Sale	42.47	8,432	358,117	1,255,297	Jan 19 09:53 PM
Esposito Pamela	Chief Business Officer	Jan 19	Sale	42.47	5,727	243,226	175,994	Jan 19 09:50 PM
Love Colin	Chief Operating Officer	Jan 19	Sale	42.46	7,857	333,589	946,524	Jan 19 09:47 PM
Esposito Pamela	Chief Business Officer	Jan 15	Option Exercise	1.01	29,273	29,566	205,267	Jan 19 09:50 PM
Omega Fund IV, L.P.	Director	Jan 15	Sale	45.19	1,916	86,584	5,325,391	Jan 19 03:02 PM
Astley-Sparke Philip	Chief Executive Officer	Jan 15	Sale	43.40	16,568	719,059	1,263,729	Jan 19 09:53 PM
Esposito Pamela	Chief Business Officer	Jan 15	Sale	43.58	29,273	1,275,717	175,994	Jan 19 09:50 PM
Love Colin	Chief Operating Officer	Jan 15	Sale	43.51	22,143	963,476	954,381	Jan 19 09:47 PM
Franchi Jean M.	Chief Financial Officer	Jan 14	Option Exercise	14.08	14,900	209,792	14,900	Jan 15 09:01 PM
Esposito Pamela	Chief Business Officer	Jan 14	Option Exercise	1.01	20,000	20,200	195,994	Jan 19 09:50 PM
Omega Fund IV, L.P.	Director	Jan 14	Sale	45.09	17,664	796,470	5,327,307	Jan 19 03:02 PM
Astley-Sparke Philip	Chief Executive Officer	Jan 14	Sale	44.42	25,000	1,110,614	1,280,297	Jan 19 09:53 PM
Esposito Pamela	Chief Business Officer	Jan 14	Sale	45.02	20,000	900,400	175,994	Jan 19 09:50 PM
Franchi Jean M.	Chief Financial Officer	Jan 14	Sale	44.53	14,900	663,465	0	Jan 15 09:01 PM
Franchi Jean M.	Chief Financial Officer	Jan 13	Option Exercise	14.08	100	1,408	100	Jan 15 09:01 PM
Franchi Jean M.	Chief Financial Officer	Jan 13	Sale	44.19	100	4,419	0	Jan 15 09:01 PM
Esposito Pamela	Chief Business Officer	Dec 23	Option Exercise	1.75	50,704	88,732	175,994	Dec 28 09:01 PM
Coffin Robert	President & Chief R&D Officer	Dec 22	Sale	40.04	220,000	8,808,800	1,804,118	Dec 28 09:03 PM
Rhodes Jason P	Director	Dec 18	Sale	41.95	4,319	181,182	19,285	Dec 22 04:38 PM
Rhodes Jason P	Director	Dec 17	Sale	42.00	11,535	484,470	19,550	Dec 17 06:21 PM
Rhodes Jason P	Director	Dec 16	Sale	42.13	12,675	533,998	20,247	Dec 17 06:21 PM
Rhodes Jason P	Director	Dec 15	Sale	42.41	40,819	1,731,253	21,013	Dec 17 06:21 PM
Franchi Jean M.	Chief Financial Officer	Dec 14	Option Exercise	14.08	25,000	352,000	25,000	Dec 16 09:00 PM
Franchi Jean M.	Chief Financial Officer	Dec 14	Sale	43.45	25,000	1,086,200	0	Dec 16 09:00 PM
Rhodes Jason P	Director	Dec 14	Sale	43.49	37,659	1,637,847	23,481	Dec 14 07:20 PM
Esposito Pamela	Chief Business Officer	Dec 11	Option Exercise	3.30	12,590	41,547	125,290	Dec 15 09:35 PM
Rhodes Jason P	Director	Dec 11	Sale	43.38	31,636	1,372,512	25,757	Dec 14 07:20 PM
Astley-Sparke Philip	Chief Executive Officer	Dec 10	Sale	43.05	25,000	1,076,145	1,305,297	Dec 11 09:00 PM
Rhodes Jason P	Director	Dec 10	Sale	43.15	34,391	1,484,083	27,669	Dec 14 07:20 PM
Astley-Sparke Philip	Chief Executive Officer	Dec 09	Sale	43.75	25,000	1,093,729	1,330,297	Dec 11 09:00 PM
Love Colin	Chief Operating Officer	Dec 09	Sale	43.75	30,000	1,312,382	976,524	Dec 11 09:00 PM
Rhodes Jason P	Director	Dec 09	Sale	43.77	41,216	1,804,182	29,748	Dec 09 07:54 PM
SLATTERY JOSEPH P	Director	Dec 08	Option Exercise	3.30	5,200	17,160	11,867	Dec 09 07:50 PM
Rhodes Jason P	Director	Dec 08	Sale	46.71	108,256	5,056,591	32,234	Dec 09 07:54 PM
SLATTERY JOSEPH P	Director	Dec 08	Sale	46.00	5,200	239,200	6,667	Dec 09 07:50 PM
Dhingra Kapil	Director	Dec 07	Option Exercise	1.75	40,000	70,000	40,000	Dec 09 07:48 PM
Rhodes Jason P	Director	Dec 07	Sale	45.96	67,890	3,120,459	35,709	Dec 09 07:54 PM
Dhingra Kapil	Director	Dec 07	Sale	45.56	40,000	1,822,395	0	Dec 09 07:48 PM
Love Colin	Chief Operating Officer	Nov 16	Sale	44.91	15,000	673,649	1,006,524	Nov 18 08:00 PM
Esposito Pamela	Chief Business Officer	Oct 14	Option Exercise	1.01	16,000	16,160	128,700	Oct 16 06:05 PM
Esposito Pamela	Chief Business Officer	Oct 14	Sale	32.90	16,000	526,410	112,700	Oct 16 06:05 PM
Love Colin	Chief Operating Officer	Sep 15	Sale	23.97	15,000	359,487	1,021,524	Sep 17 04:25 PM
Esposito Pamela	Chief Business Officer	Aug 31	Option Exercise	1.01	5,000	5,050	117,700	Sep 01 05:13 PM
Esposito Pamela	Chief Business Officer	Aug 31	Sale	27.05	5,000	135,250	112,700	Sep 01 05:13 PM
Love Colin	Chief Operating Officer	Aug 17	Sale	23.44	15,000	351,555	1,036,524	Aug 18 05:15 PM
Coffin Robert	President & Chief R&D Officer	Jul 09	Sale	22.13	169,750	3,757,295	2,024,118	Jul 10 09:00 PM
Coffin Robert	Pres & Chief Res & Dev Officer	Feb 20	Sale	17.04	24,250	413,220	2,193,868	Feb 24 04:02 PM
Coffin Robert	Pres & Chief Res & Dev Officer	Feb 12	Sale	17.04	48,500	826,198	2,218,118	Feb 14 04:00 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience